{"id":"W2007734777","doi":"10.1089/cbr.2000.15.15","title":"Pretargeted Radioimmunotherapy (PRIT™) for Treatment of Non-Hodgkin's Lymphoma (NHL): Initial Phase I/II Study Results","year":2000,"lang":"en","type":"article","venue":"Cancer Biotherapy and Radiopharmaceuticals","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Radioimmunotherapy; Pretargeting; Medicine; Biodistribution; Conjugate; Nuclear medicine; Rituximab; Lymphoma; Pharmacokinetics; Antibody; Internal medicine; Chemistry; Monoclonal antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001382794,0.0008722836,0.00151623,0.0002890702,0.0002645931,0.0006586519,0.0005443855,0.0006209269,0.001170029],"category_scores_gemma":[0.0005437538,0.0002990701,0.0006678371,0.0002383282,0.0004735001,0.0003947532,0.0001975808,0.001569499,0.0003967068],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006104306,"about_ca_system_score_gemma":0.0007138212,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007146305,"about_ca_topic_score_gemma":0.001413776,"domain_scores_codex":[0.999572,0.0002001371,0.00001714087,0.00005380978,0.00005521486,0.000101774],"domain_scores_gemma":[0.9996471,0.00008269727,0.00004638595,0.00003532008,0.00004637648,0.0001420843],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1925043,0.07467586,0.01623351,0.001523208,0.001453555,0.0008957034,0.001106046,0.004595747,0.2241959,0.0004945775,0.004723053,0.4775985],"study_design_scores_gemma":[0.04795657,0.8904532,0.02370127,0.00005405766,0.0006826393,0.0007946102,0.00007750273,0.001180918,0.02707316,0.0001103635,0.007885852,0.00002979219],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877248,0.006555201,0.001551533,0.0002321517,0.00005562377,0.001584587,0.0003888117,0.0001306724,0.001776637],"genre_scores_gemma":[0.9875838,0.00423921,0.002068642,0.0006491001,0.0001300225,0.0016347,0.001615158,0.00003696706,0.00204244],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00151623,"threshold_uncertainty_score":0.007313013,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07038171382198578,"score_gpt":0.4769027952507788,"score_spread":0.406521081428793,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}